LABT Company Profile and Key Details

Average 10-day trading volume of 235.84 thousand shares is in line with the 3-month average of 246.21 thousand, indicating normal recent market interest.

Our AI price prediction model suggests that Lakewood-Amedex Biotherapeutics Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -90.32%, with price expected at $0.18 by August 04, 2026, within a range of $0.00 to $1.23 3-Month Outlook: Projected fall of -99.46%, reaching $0.01 by October 19, 2026, with a range of $0.00 to $0.15. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by July 21, 2027, within a range of $0.00 to $0.29.

Our AI forecast model points to short-term weakness (-90.32% over two weeks), a medium-term fall (-99.46% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ:LABT) closed at $3.41 USD, gaining $1.55 (83.33%) from the previous close of $1.86. The stock is currently mid-range between its 52-week high and low $0.37 and $9.26. With a market capitalization of about $1.60 million, Lakewood-Amedex Biotherapeutics Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Headquartered in University Park, FL, Lakewood-Amedex Biotherapeutics Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Kelvin Cooper, the company employs approximately 5 people and listed since April 23, 2026. This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies.

Dividend and splits history remains an important factor for investors monitoring long-term returns.